Alcobra Pharma Ltd. (Nasdaq: ADHD) has claimed positive results in a Phase III study of Metadoxine Extended Release (MDX) in adults with Attention Deficit Hyperactivity Disorder (ADHD).
However, the market has not received the results enthusiastically, and having fallen 7.35% on Friday, the share price was down a further 45.36% in premarket trading to $7.71, giving a market cap of $192.77 million.
Alcobra said that in a modified Intent To Treat (mITT) population, MDX demonstrated a statistically significant improvement in ADHD symptoms compared to placebo as measured by the Conner's Adult ADHD Rating Scale. But Alcobra added that it had removed four placebo patients from the analysis because of "extreme" responses.
The 300-patient, randomized, placebo-controlled study was conducted at 18 sites in the US and 2 in Israel.
Published by Globes [online], Israel business news - www.globes-online.com - on October 6, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014